Published in:
01-02-2013 | Correspondence
Clinical significance of infections caused by plasmid-mediated AmpC β-lactamases and extended-spectrum β-lactamase-producing Escherichia coli
Authors:
H. S. Cheong, K. S. Ko, C.-I. Kang, D. R. Chung, K. R. Peck, J.-H. Song
Published in:
Infection
|
Issue 1/2013
Login to get access
Excerpt
Escherichia coli frequently causes both nosocomial and community-acquired infections, and antimicrobial resistance in
E. coli is a growing problem worldwide. Resistance to broad-spectrum antibiotics in
E. coli is often mediated by the production of extended-spectrum β-lactamases (ESBLs) [
1]. In recent years, some
E. coli strains have been isolated that harbor plasmid-mediated AmpC genes imported from other
Enterobacteriaceae carrying chromosomal AmpC genes, such as
Citrobacter freundii,
Enterobacter cloacae, and
Aeromonas species [
2]. Recent studies on plasmid-mediated AmpC β-lactamase (PAB)-producing
E. coli have shown only the prevalence of PAB [
3‐
6]. Furthermore, most previous studies regarding PAB-producing
E. coli have involved all clinical isolates, including colonized pathogens [
1,
4‐
6]. …
